Neut/Lymph Ratio

Optimal result: 0 – 2.9 Ratio

NLR has been extensively evaluated and shown to be associated with outcome and predict disease course among patients with a variety of medical conditions including ischemic stroke, cerebral hemorrhage, major cardiac events and sepsis and infectious diseases. Furthermore, in cancer patients higher NLR has been associated with poor prognosis. These adverse associations may reflect the contributions of severe inflammation and poor immune function to the progression of these diseases.

Several studies have reported that higher NLR was significantly associated with overall mortality and mortality due to cardiovascular disease, but not with mortality due to cancer. In addition, it is important to evaluate associations of NLR with cause-specific mortality over different intervals of follow-up time, because associations over short intervals after baseline measurement of NLR predominantly reflect the effects of disordered inflammation or immunity for people who already have these medical conditions.

NLR (Neutrophil to Lymphocyte Ratio) is a biomarker that can be used as an indication of subclinical inflammation. NLR is a calculation based on the Absolute Neutrophil Count divided by the Absolute Lymphocyte Count determined by the peripheral blood CBC differential. This calculation, according to recent literature, is useful in assessing the likelihood of severe progression of disease in SARS-CoV-2 positive patients.

The neutrophil-to-lymphocyte ratio (NLR), calculated as a simple ratio between the neutrophil and lymphocyte counts measured in peripheral blood, is a biomarker which reflects the balance between two aspects of the immune system: acute and chronic inflammation (as indicated by the neutrophil count) and adaptive immunity (lymphocyte count).

NLR has been extensively evaluated and shown to be associated with outcome and predict disease course among patients with a variety of medical conditions including ischemic stroke, cerebral hemorrhage, major cardiac events and sepsis and infectious diseases. Furthermore, in cancer patients higher NLR has been associated with poor prognosis. These adverse associations may reflect the contributions of severe inflammation and poor immune function to the progression of these diseases.

By extension, NLR may be predictive of mortality in the general population, and thus the overall impact of inflammation and immunity on health. Several studies have reported that higher NLR was significantly associated with overall mortality and mortality due to cardiovascular disease, but not with mortality due to cancer. In addition, it is important to evaluate associations of NLR with cause-specific mortality over different intervals of follow-up time, because associations over short intervals after baseline measurement of NLR predominantly reflect the effects of disordered inflammation or immunity for people who already have these medical conditions. In contrast, associations over intervals of several years reflect effects of these processes on both the incidence of disease and survival after diagnosis. While some studies have assessed associations over different follow-up intervals for mortality due to cardiovascular disease, cancer or stroke, no study has systematically assessed such associations for multiple diseases.

Additional notes:

The NLR should always be interpreted in the clinical context of the patient and not be used in isolation to diagnose or rule-out disease, however it may be a more useful test than ones medicine routinely uses, like the WBC.

References:

Song, M., Graubard, B.I., Rabkin, C.S. et al. Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep 11, 464 (2021). https://doi.org/10.1038/s41598-020-79431-7 [L]

Neut/Lymph Ratio
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Neut/Lymph Ratio — 10,000+ markers explained
One Neut/Lymph Ratio result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro